Structure Therapeutics Inc. (GPCR)
| Market Cap | 3.27B +178.0% |
| Revenue (ttm) | n/a |
| Net Income | -141.20M |
| EPS | -2.39 |
| Shares Out | 70.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 702,405 |
| Open | 47.42 |
| Previous Close | 48.13 |
| Day's Range | 46.00 - 48.28 |
| 52-Week Range | 13.22 - 94.90 |
| Beta | -1.90 |
| Analysts | Strong Buy |
| Price Target | 103.36 (+123.72%) |
| Earnings Date | May 7, 2026 |
About GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for GPCR stock is "Strong Buy." The 12-month stock price target is $103.36, which is an increase of 123.72% from the latest price.
News
Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target
Structure Therapeutics (GPCR) reported highly positive Phase 2 ACCESS II data for aleniglipron, achieving ~16% placebo-adjusted weight loss with strong statistical significance and no plateau. Alenigl...
Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript
Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript
Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate?
Structure Therapeutics said its GLP-1 pill helped patients lose more than 16% of their body weight in a midstage trial, outperforming results reported for competing obesity drugs.
Structure Therapeutics Stock Explodes As Much-Awaited Experimental Oral Drug Trial Shows Weight Loss Of 16%
The stock's rise comes as the company reported significant weight loss results from its investigational oral drug, aleniglipron, which is designed for treating obesity, while broader markets experienc...
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral G...
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks
Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough?
Structure Therapeutics Inc. has evolved from a “dark horse” to a leading contender in the oral GLP-1 obesity drug market. GPCR's market cap surged from $1.3B to $5B in five months, reflecting heighten...
Obesity stocks slump on Novo's underwhelming 2026 sales forecast
Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-...
Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s
Structure Therapeutics CEO Ray Stevens talked about the biotech's path forward and his expectations for the future of the booming GLP-1 space.
Structure CEO Ray Stevens talks its obesity drug portfolio
Ray Stevens, Structure CEO, joins 'Fast Money' to talk its weigh-loss drug pipeline, potential M&A, and more.
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs
SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met...
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met...
Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)
Structure Therapeutics (GPCR) delivered robust Phase 2b results for aleniglipron, surpassing key efficacy and tolerability thresholds for oral GLP-1 therapies. GPCR now appears competitive with top or...
Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript
Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript
Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at...
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met...
Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump
Structure Therapeutics Inc. (NASDAQ:GPCR) shares shot up 100% to $68.95 after the company announced topline data from the ACCESS clinical program of aleniglipron for the treatment of people living wit...
Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?
Structure Therapeutics stock (NASDAQ: GPCR) rocketed above 103% Monday, trading near $70, after the clinical-stage biotech released promising mid-stage results for its oral obesity drug, aleniglipron....
Structure's experimental pill shows 11% weight loss in study, shares up
Structure Therapeutics said on Monday that its obesity pill showed a 11.3% reduction in weight in a mid-stage study.
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met...
Final Trade: UBER, CRWV, GPCR, DIS
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025
Fast Money: DAL, ROKU, AAPL, GPCR
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Structure Therapeutics Inc. (NASDAQ:GPCR) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Raymond Stevens - CEO & Director Conference Call...